Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 11 | 2017 | 212 | 1.340 |
Why?
|
| Influenza Vaccines | 7 | 2017 | 101 | 1.080 |
Why?
|
| Antibodies, Viral | 7 | 2017 | 325 | 1.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 8 | 2017 | 92 | 0.820 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2017 | 29 | 0.670 |
Why?
|
| Complement System Proteins | 3 | 2015 | 107 | 0.520 |
Why?
|
| HLA-B35 Antigen | 2 | 2009 | 3 | 0.480 |
Why?
|
| Yellow Fever Vaccine | 2 | 2009 | 5 | 0.480 |
Why?
|
| Antibodies, Neutralizing | 3 | 2012 | 218 | 0.410 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 1012 | 0.400 |
Why?
|
| Vaccines, Inactivated | 3 | 2016 | 14 | 0.390 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2022 | 185 | 0.390 |
Why?
|
| Yellow fever virus | 2 | 2009 | 5 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2009 | 681 | 0.310 |
Why?
|
| Vaccination | 3 | 2016 | 378 | 0.310 |
Why?
|
| Yellow Fever | 1 | 2009 | 4 | 0.300 |
Why?
|
| Lymphocyte Activation | 2 | 2008 | 757 | 0.280 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 4 | 2017 | 13 | 0.240 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2017 | 29 | 0.240 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2009 | 94 | 0.240 |
Why?
|
| Interferon-gamma | 4 | 2009 | 582 | 0.200 |
Why?
|
| Influenza A virus | 2 | 2014 | 126 | 0.180 |
Why?
|
| Viral Structural Proteins | 1 | 2002 | 17 | 0.180 |
Why?
|
| Cross Reactions | 4 | 2017 | 137 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 180 | 0.170 |
Why?
|
| Viral Matrix Proteins | 3 | 2009 | 50 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2022 | 645 | 0.160 |
Why?
|
| Viral Proteins | 2 | 2013 | 270 | 0.150 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 2 | 2017 | 7 | 0.150 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 214 | 0.130 |
Why?
|
| Viral Core Proteins | 1 | 2017 | 30 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 2 | 2016 | 236 | 0.120 |
Why?
|
| Infant | 3 | 2017 | 1718 | 0.120 |
Why?
|
| Humans | 18 | 2022 | 65554 | 0.120 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2016 | 72 | 0.120 |
Why?
|
| Cell Line | 4 | 2009 | 2068 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2017 | 2077 | 0.110 |
Why?
|
| Adult | 8 | 2017 | 17417 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2016 | 245 | 0.110 |
Why?
|
| Hemagglutinins | 2 | 2017 | 17 | 0.110 |
Why?
|
| Cytokines | 2 | 2009 | 956 | 0.110 |
Why?
|
| Nucleocapsid Proteins | 2 | 2017 | 36 | 0.100 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2013 | 18 | 0.100 |
Why?
|
| Influenza B virus | 1 | 2013 | 10 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 458 | 0.100 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2012 | 9 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 160 | 0.090 |
Why?
|
| Antibody Formation | 1 | 2012 | 112 | 0.090 |
Why?
|
| Bipolar Disorder | 1 | 2014 | 249 | 0.090 |
Why?
|
| Child | 3 | 2017 | 4681 | 0.080 |
Why?
|
| Alleles | 2 | 2022 | 457 | 0.080 |
Why?
|
| Young Adult | 3 | 2017 | 4831 | 0.080 |
Why?
|
| Aging | 1 | 2016 | 766 | 0.080 |
Why?
|
| Middle Aged | 5 | 2017 | 18277 | 0.080 |
Why?
|
| Infection Control | 1 | 2011 | 105 | 0.080 |
Why?
|
| Male | 6 | 2016 | 31083 | 0.070 |
Why?
|
| Biomarkers | 1 | 2014 | 1473 | 0.070 |
Why?
|
| Drug Industry | 1 | 2008 | 43 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 2009 | 102 | 0.070 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2008 | 10 | 0.070 |
Why?
|
| CD8 Antigens | 1 | 2008 | 54 | 0.070 |
Why?
|
| Female | 6 | 2016 | 34131 | 0.070 |
Why?
|
| Immunization, Secondary | 1 | 2008 | 51 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2008 | 59 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2014 | 2632 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 72 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2008 | 103 | 0.070 |
Why?
|
| Neutralization Tests | 1 | 2008 | 127 | 0.070 |
Why?
|
| AIDS Vaccines | 1 | 2008 | 73 | 0.070 |
Why?
|
| Vaccines, DNA | 1 | 2008 | 98 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 421 | 0.060 |
Why?
|
| Kinetics | 1 | 2009 | 768 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 877 | 0.060 |
Why?
|
| Critical Care | 1 | 2011 | 410 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2014 | 3355 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 443 | 0.060 |
Why?
|
| Pandemics | 1 | 2011 | 676 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2008 | 290 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 5620 | 0.050 |
Why?
|
| Neuraminidase | 2 | 2017 | 43 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 63 | 0.050 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 2002 | 40 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2002 | 36 | 0.050 |
Why?
|
| RNA Helicases | 1 | 2002 | 98 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2002 | 124 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2002 | 131 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 292 | 0.040 |
Why?
|
| Aged | 1 | 2014 | 14958 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 27 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 80 | 0.030 |
Why?
|
| Hemagglutination Tests | 1 | 2015 | 3 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 6377 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 713 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2016 | 242 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 461 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2016 | 534 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1592 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1156 | 0.020 |
Why?
|
| Macrophages | 1 | 2016 | 1060 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 290 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 424 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 32 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2009 | 52 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 145 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2008 | 19 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3468 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2008 | 32 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 40 | 0.020 |
Why?
|
| Saponins | 1 | 2008 | 29 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2008 | 64 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2009 | 142 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 2016 | 0.020 |
Why?
|
| Vasculitis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2011 | 423 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 369 | 0.020 |
Why?
|
| Pregnancy | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 424 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5441 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11209 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 21533 | 0.010 |
Why?
|